Phase I–II Study of Hypofractionated Simultaneous Integrated Boost With Tomotherapy for Prostate Cancer

Muzio, N. Di; Fiorino, Claudio; Cozzarini, C.; Alongi, Filippo; Broggi, S.; Mangili, P.; Guazzoni, G.; Valdagni, Riccardo; Calandrino, R.; Fazio, Ferruccio

doi:10.1016/j.ijrobp.2008.08.038

Cited by 58 publications

(35 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…95% of the PTV volume received at least 95% of the prescribed dose. Normal tissue constraints from published intensity-modulated radiotherapy (IMRT) studies [1,2,21] were adopted; in addition, planning optimization was always stressed to obtain the lowest dose possible for every OAR without compromising target coverage, an approach that we usually follow during tomotherapy optimization [7,11,12].…”

Section: Imaging Contouring and Planning Proceduresmentioning

confidence: 99%

PET-guided dose escalation tomotherapy in malignant pleural mesothelioma

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Imaging Contouring and Planning Proceduresmentioning

confidence: 99%

PET-guided dose escalation tomotherapy in malignant pleural mesothelioma

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…The reduction of the fraction of rectum receiving intermediate-low doses may be one of the causes of the very mild acute GI toxicity profiles experienced by both TOMOADV [3] and TOMOSIB [17] patients, as suggested by recent investigations about dose-volume relationships for acute rectal toxicity (see for instance [18]), suggesting a parallel behaviour for this endpoint.…”

Section: Discussionmentioning

confidence: 90%

Physics aspects of prostate tomotherapy: Planning optimization and image-guidance issues

et al. 2008

Self Cite

View full text Add to dashboard Cite

“…In this study, all patients were treated with HT, a special form of IMRT which can produce a well-distributed dose in the PTV with effective sparing of OARs and can, therefore, reduce the incidence of side effects, as shown by a number of studies. [13][14][15][16] However, the sharp gradient of dose at the margin of the PTV can be a double-edged sword. The deviations that may happen in daily treatments require a certain expansion of CTV to guarantee effective target coverage.…”

Section: Discussionmentioning

confidence: 99%

Hypofractionated Helical Tomotherapy for Older Aged Patients With Prostate Cancer

Liu

Wang

et al. 2016

Technol Cancer Res Treat

View full text Add to dashboard Cite

In our center, the feasibility and related acute toxicities of hypofractionated helical tomotherapy have been evaluated in older aged patients with prostate cancer . Between February 2009 and February 2014, 67 patients (older than 65 years) were enrolled in a prospective phase I-II study (registered number, ChiCTR-ONC-13004037). Patients in cohort 1 (n ¼ 33) and cohort 2 (n ¼ 34) received 76 Gy in 34 fractions (2.25 Gy/F) and 71.6 Gy in 28 fractions (2.65 Gy/F), respectively, to the prostate and seminal vesicles, while 25 patients in cohort 2 also received integrated elective lymph node irradiation (50.4 Gy). All patients were treated with helical tomotherapy, and daily image guidance was performed before each treatment. Acute toxicities were assessed with Radiation Therapy Oncology Group (RTOG)/European Organization for Research on Treatment of Cancer (EORTC) criteria. No significant difference was detected between the 2 cohorts in the incidence of acute toxicities. In cohort 1, the incidences of grade 1 and 2 genitourinary and gastrointestinal toxicities were 45.5% and 45.4%, respectively, and without grade 3 and 4 toxicities. In cohort 2, the incidences of acute grade 1 and 2 genitourinary and gastrointestinal toxicities were 47.1% and 55.9%, respectively, and grade 3 genitourinary toxicity (hematuria) was noted only in 1 patient. No significant difference was detected in the incidence of acute toxicities between the patients receiving integrated elective lymph node irradiation and those receiving irradiation to prostate and seminal vesicle in cohort 2. Univariate and multivariate analyses were performed with clinical parameters. Only the baseline weight was found negatively correlated with genitourinary toxicities at a weak level (relative risk ¼ 0.946, 95% confidence interval 0.896-0.998], P ¼ .043). This study shows that 2 hypofractionation regimens (76 Gy/34F and 71.6 Gy/28F) delivered with HT are well tolerated in older aged patients having prostate cancer without significant difference for acute toxicities between the 2 cohorts. Late toxicities and treatment outcomes for these patients are under investigation.

show abstract

Phase I–II Study of Hypofractionated Simultaneous Integrated Boost With Tomotherapy for Prostate Cancer

Cited by 58 publications

References 36 publications

PET-guided dose escalation tomotherapy in malignant pleural mesothelioma

PET-guided dose escalation tomotherapy in malignant pleural mesothelioma

Physics aspects of prostate tomotherapy: Planning optimization and image-guidance issues

Hypofractionated Helical Tomotherapy for Older Aged Patients With Prostate Cancer

Contact Info

Product

Resources

About